These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17030589)

  • 1. Screening designs for drug development.
    Rossell D; Müller P; Rosner GL
    Biostatistics; 2007 Jul; 8(3):595-608. PubMed ID: 17030589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian optimal design for phase II screening trials.
    Ding M; Rosner GL; Müller P
    Biometrics; 2008 Sep; 64(3):886-894. PubMed ID: 18162113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision theoretic designs for phase II clinical trials with multiple outcomes.
    Stallard N; Thall PF; Whitehead J
    Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
    Zohar S; Chevret S
    J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
    Zhou H; Chen C; Sun L; Yuan Y
    Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
    Bekele BN; Shen Y
    Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian decision-theoretic sequential response-adaptive randomization design.
    Jiang F; Jack Lee J; Müller P
    Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the flexibility and efficiency of phase II designs for oncology trials.
    Englert S; Kieser M
    Biometrics; 2012 Sep; 68(3):886-92. PubMed ID: 22150825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.